JP5349722B2 - 金属結合化合物およびその使用方法 - Google Patents

金属結合化合物およびその使用方法 Download PDF

Info

Publication number
JP5349722B2
JP5349722B2 JP2001528205A JP2001528205A JP5349722B2 JP 5349722 B2 JP5349722 B2 JP 5349722B2 JP 2001528205 A JP2001528205 A JP 2001528205A JP 2001528205 A JP2001528205 A JP 2001528205A JP 5349722 B2 JP5349722 B2 JP 5349722B2
Authority
JP
Japan
Prior art keywords
peptide
metal
animal
functional group
metal binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001528205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528814A (ja
JP2003528814A5 (enExample
Inventor
バー−オア、デイビッド
カーチス、シー．ゲラルド
ロー、エドワード
ケイ．アール． ラオ、ナガラジャ
ブイ． ウィンクラー、ジェームズ
エム． クルック、ワンネル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMI Biosciences Inc
Original Assignee
DMI Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26854102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5349722(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DMI Biosciences Inc filed Critical DMI Biosciences Inc
Publication of JP2003528814A publication Critical patent/JP2003528814A/ja
Publication of JP2003528814A5 publication Critical patent/JP2003528814A5/ja
Application granted granted Critical
Publication of JP5349722B2 publication Critical patent/JP5349722B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2001528205A 1999-10-01 2000-09-29 金属結合化合物およびその使用方法 Expired - Fee Related JP5349722B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15740499P 1999-10-01 1999-10-01
US60/157,404 1999-10-01
US21107800P 2000-06-13 2000-06-13
US60/211,078 2000-06-13
PCT/US2000/026952 WO2001025265A1 (en) 1999-10-01 2000-09-29 Metal-binding compounds and uses therefor

Publications (3)

Publication Number Publication Date
JP2003528814A JP2003528814A (ja) 2003-09-30
JP2003528814A5 JP2003528814A5 (enExample) 2007-11-15
JP5349722B2 true JP5349722B2 (ja) 2013-11-20

Family

ID=26854102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001528205A Expired - Fee Related JP5349722B2 (ja) 1999-10-01 2000-09-29 金属結合化合物およびその使用方法

Country Status (11)

Country Link
EP (2) EP2327713A1 (enExample)
JP (1) JP5349722B2 (enExample)
KR (6) KR101312880B1 (enExample)
CN (2) CN102038932B (enExample)
AT (1) ATE553116T1 (enExample)
AU (1) AU770999C (enExample)
BR (1) BR0014389A (enExample)
CA (1) CA2385551A1 (enExample)
IL (4) IL148797A0 (enExample)
NZ (1) NZ518266A (enExample)
WO (1) WO2001025265A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040602A1 (en) * 2001-04-30 2003-02-27 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1406 daltons
US20020160417A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons
CA2467747A1 (en) * 2001-11-20 2003-05-30 Dmi Biosciences, Inc. Methods and products for oral care
AU2003299568B2 (en) 2002-11-27 2010-07-22 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
KR101430627B1 (ko) 2008-05-13 2014-08-14 유니버시티 오브 캔사스 금속 추출 펩타이드(ｍａｐ) 태그 및 관련된 방법
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
CN112094316B (zh) * 2017-06-29 2022-04-08 安徽省农业科学院农产品加工研究所 一种Ser和Cys分列在两端的高锌螯合活性锌鳌合肽及其应用
CN113563418B (zh) * 2021-06-22 2023-03-03 中国科学院化学研究所 一种原位响应ros的人工酶及其制备方法与应用
CN114437175B (zh) * 2022-01-29 2023-09-29 山东第一医科大学第三附属医院(山东省医学科学院附属医院) 一种肽探针及其应用和包含该肽探针的试剂盒

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4022888A (en) 1975-09-09 1977-05-10 Diagnostic Data, Inc. Esterified orgotein
US4461724A (en) 1981-10-28 1984-07-24 Nippon Zoki Pharmaceutical Co., Ltd. Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them
US4912118A (en) 1983-09-23 1990-03-27 National Research Development Corporation Pharmaceutical compositions
US4760051A (en) 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
US4665054A (en) 1985-02-08 1987-05-12 Bioheal, Inc. Chemical derivatives of GHL-Cu
US5348943A (en) 1985-02-08 1994-09-20 Procyte Corporation Cosmetic and skin treatment compositions
US4767753A (en) 1985-02-08 1988-08-30 Procyte Corporation Methods and compositions for preventing ulcers
US5177061A (en) 1985-02-08 1993-01-05 Procyte Corporation Method for stimulating hair growth using GHL-Cu complexes
US4810693A (en) 1985-02-08 1989-03-07 Procyte Corporation Method for inducing biological coverings in wounds
US4877770A (en) 1985-02-08 1989-10-31 Procyte Corporation Chemical derivatives of GHL-Cu
US5214032A (en) 1985-02-08 1993-05-25 Procyte Corporation GHL-CU pharmaceutical compositions and compounds
US5550183A (en) 1985-02-08 1996-08-27 Procyte Corporation Metal-peptide compositions and methods for stimulating hair growth
US5120831A (en) 1985-02-08 1992-06-09 Procyte Corporation Metal-peptide compositions
US5422096A (en) 1985-05-08 1995-06-06 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
JPS62116565A (ja) * 1985-11-15 1987-05-28 Fujisawa Pharmaceut Co Ltd 新規ペプチド
GB8603537D0 (en) 1986-02-13 1986-03-19 Parker D Conjugate compound
JP2604457B2 (ja) 1987-05-11 1997-04-30 プロサイト コーポレイション 毛の成長の刺激方法
DE68917946T2 (de) 1988-01-29 1995-01-05 Peter H Proctor Haarwachstumanregung mit Nitroxyd und anderen Radikalen.
US5101041A (en) 1989-04-26 1992-03-31 The Curators Of The University Of Missouri Triamines and their derivatives as bifunctional chelating agents
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5759515A (en) 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
US5145838A (en) 1989-08-30 1992-09-08 Procyte Corporation Methods and compositions for healing ulcers
US5023237A (en) 1989-08-30 1991-06-11 Procyte Corporation Methods and compositions for healing ulcers
US5059588A (en) 1989-10-13 1991-10-22 Procyte Corporation, Incorporated Methods and compositions for healing bone using gly his lys: copper
US5118665A (en) 1990-02-09 1992-06-02 Procyte Corporation Anti-oxidative and anti-inflammatory metal:peptide complexes and uses thereof
US5164367A (en) 1990-03-26 1992-11-17 Procyte Corporation Method of using copper(ii) containing compounds to accelerate wound healing
US5252559A (en) 1991-08-20 1993-10-12 The Procter & Gamble Company His-Gly-Gly peptide and derivatives thereof for hair growth
US5280038A (en) 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
CA2094785A1 (en) 1992-05-08 1993-11-09 Jean Gariepy Metal chelating peptide
US5807535A (en) 1992-07-31 1998-09-15 Australian Nuclear Science & Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
US5380747A (en) 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5464934A (en) 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5476939A (en) 1993-12-30 1995-12-19 Abbott Laboratories Certain pyridyl and isoquinolyl carbinolamine derivatives
JPH07316192A (ja) 1994-05-27 1995-12-05 Hoechst Japan Ltd Ｌ−リシル−グリシル−ｌ−ヒスチジンおよびこれを含有する創傷治療剤
US5538945A (en) 1994-06-17 1996-07-23 Procyte Corporation Stimulation of hair growth by peptide copper complexes
US5891418A (en) 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
EP0841951A2 (en) 1995-06-26 1998-05-20 Concat Ltd. Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
US5637311A (en) 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US5786335A (en) 1995-11-06 1998-07-28 Warner-Lambert Company Sulfhydryl containing peptides for treating vascular disease
US5928955A (en) 1996-03-22 1999-07-27 California Institute Of Technology Peptidyl fluorescent chemosensor for divalent zinc
AR007200A1 (es) 1996-05-21 1999-10-13 Novartis Ag Derivados de acido n,n'-di(2-hidroxibencil)etilendiamina-n,n'-diacetico, su aplicacion, su empleo, procedimiento para elaborarlos y preparacionesfarmaceuticas que contienen a dichos derivados.
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
PL184070B1 (pl) 1996-07-30 2002-08-30 Politechnika Lodzka Sposób wytwarzania peptydów zawierających a-hydroksymetyloserynę
US5906996A (en) 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
US5922761A (en) 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
US5739395A (en) 1997-01-10 1998-04-14 University Of Florida Research Foundation, Inc. Method for synthesis of rhizoferrin
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
CA2319255C (en) 1998-02-04 2010-01-26 University Of Florida Research Foundation, Inc. Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy
DE19819843A1 (de) 1998-05-05 1999-11-11 Biotechnolog Forschung Gmbh Metallchelat bindende Peptide
AU755564B2 (en) 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy

Also Published As

Publication number Publication date
KR20110049875A (ko) 2011-05-12
IL148797A (en) 2010-12-30
AU770999B2 (en) 2004-03-11
KR101062041B1 (ko) 2011-09-02
KR20020057966A (ko) 2002-07-12
KR101312880B1 (ko) 2013-09-30
JP2003528814A (ja) 2003-09-30
CA2385551A1 (en) 2001-04-12
KR20090086437A (ko) 2009-08-12
CN102038932A (zh) 2011-05-04
ATE553116T1 (de) 2012-04-15
AU770999C (en) 2005-04-21
KR20120023147A (ko) 2012-03-12
KR101353140B1 (ko) 2014-01-20
IL148797A0 (en) 2002-09-12
KR20120024890A (ko) 2012-03-14
HK1157635A1 (en) 2012-07-06
BR0014389A (pt) 2002-10-29
KR20100075503A (ko) 2010-07-02
CN102038932B (zh) 2013-11-06
CN1390231A (zh) 2003-01-08
NZ518266A (en) 2005-01-28
IL202812A0 (en) 2011-07-31
EP1220870B1 (en) 2012-04-11
AU7740700A (en) 2001-05-10
EP1220870A4 (en) 2004-04-07
EP1220870A1 (en) 2002-07-10
WO2001025265A1 (en) 2001-04-12
IL207923A0 (en) 2011-07-31
EP2327713A1 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
US8017728B2 (en) Metal-binding compounds and uses therefor
US7973008B2 (en) Metal-binding compounds and uses therefor
US20030130185A1 (en) Metal-binding compounds and uses therefor
RU2582247C2 (ru) Ингибиторы апоптоза и их применение
JP5349722B2 (ja) 金属結合化合物およびその使用方法
JP2004535461A (ja) プロテインｃの不活性化を抑制するための銅キレート剤の使用
WO2002064620A2 (en) Metal-binding compounds and uses therefor
HK1158230A (en) Metal-binding compounds and uses therefor
HK1157635B (en) Metal-binding compounds and uses thereof
JPH03141297A (ja) イミダゾール化合物およびトランスグルタミナーゼ阻害剤としてのその使用
HK1051049A (en) Metal-binding compounds and uses thereof
HK1191025A (en) Inhibitors of apoptosis and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110506

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130821

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S631 Written request for registration of reclamation of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313631

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees